Dr Reece Caldwell

Consultant medical oncologist

Primary medical qualifications:

BSc, MBBS, FRACP

GMC number:

7618725

Specialities:

Chemotherapy

Reece Caldwell

Background

Medical oncologist specialising in:

1. Urological malignancies (prostate, bladder renal)
2. Ovarian germ cell tumours
3. Gestational trophoblastic disease and
4. Rare cancers
5. Acute oncology and rapid diagnostic service for suspected new cancers

Mr Caldwell completed a Fellowship in drug development at the Royal Marsden Hospital, and a Fellowship in rare cancers at the Royal Melbourne Hospital.

Expertise

Prostate cancer, renal cancer, bladder cancer, ovarian germ cell tumours, gestational trophoblastic disease.

Research & publications

First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors
TA Yap, DSP Tan, A Terbuch, R Caldwell, C Guo, BC Goh, V Heong, ...
Cancer discovery 11 (1), 80-91

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
C Guo, A Sharp, B Gurel, M Crespo, I Figueiredo, S Jain, U Vogl, ...
Nature 623 (7989), 1053-1061

Abstract CT143: Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers. R Shinde, A Terbuch, M Little, R Caldwell, R Kurup, R Riisnaes, M Crespo, ...
Cancer Research 80 (16_Supplement), CT143-CT143

Targeting homologous recombination deficiency in uterine leiomyosarcoma
G Dall, CJ Vandenberg, K Nesic, G Ratnayake, W Zhu, JHA Vissers, ...
Journal of Experimental & Clinical Cancer Research 42 (1), 112

Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers R Shinde, A Terbuch, M Little, R Caldwell, R Kurup, R Riisnaes, M Crespo, ...
Cancer Res 80 (16 Suppl)

Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial
S Banerjee, MG Krebs, A Greystoke, AI Garces, VS Perez, A Terbuch, ...
Nature Medicine, 1-7

Abstract CT129: HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab …
D Papadatos-Pastos, A Pal, M Akay, M Ameratunga, S Mithra, JE Ang, ...
Cancer Research 80 (16_Supplement), CT129-CT129

Monitoring complete hydatidiform molar pregnancies after normalisation of human chorionic gonadotrophin: national retrospective population study
BE Swift, L Coopmans, K Singh, C Coyle, EH Wilkes, I Jabbar, G Maher, ...
BMJ medicine 4 (1), e001017

Regulatory approvals for genitourinary (GU) cancer by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) over 20 years (2003-2023).
S Khanna, N Sarwar, R Caldwell, J Krell, DJ Benjamin, MJ Hadfield, ...
Journal of Clinical Oncology 42 (4_suppl), 432-432

Two years of the Australian Rare Cancer Portal: a national referral service for rare cancer information and research.
CL Georgiou, D Kee, L Papadopoulos, R Caldwell, A Bourne, J Haurat, ...
Journal of Clinical Oncology 40 (16_suppl), e18581-e18581

Clinical impact of molecular profiling of cervical cancer (CC) patients (pts) in a dedicated phase I (P1) unit
M Scaranti, R Caldwell, MS Miralles, R Shinde, A Pal, JE Ang, A Biondo, ...
Annals of Oncology 30, v430

10-year retrospective review of surgical outcomes in patients undergoing hysterectomy for gestational trophoblastic disease at a tertiary centre in London
G Lockett, A Daruwalla, L Bremner, Z Velji, N Cooper, B Kaur, F Sorbi, ...
Bjog-An International Journal Of Obstetrics And Gynaecology 132, 101-101

Ultrasound imaging and hysteroscopy findings in patients referred with atypical placental site nodule to a tertiary gestational trophoblastic centre
G Lockett, A Thomson, Z Velji, N Cooper, C Landolfo, M Al-Memar, ...
Bjog-An International Journal Of Obstetrics And Gynaecology 132, 101-

21P Squamous cell carcinoma arising from germ cell tumour of the ovary treated with immunotherapy
RD Caldwell, O Solheim, N Sarwar, E Ghorani, B Kaur, S Saso, M Seckl
ESMO Open 10

45MO Management of stage I ovarian Sertoli-Leydig cell tumors: Prognostic factors from a multicenter international retrospective study
A Bergamini, G Sabetta, R Fruscio, B Kaur, G Cormio, N Sarwar, ...
ESMO Open 9